Is it possible to prevent chemotherapy-induced heart failure with cardiovascular drugs - the review of the current clinical evidence

References

• World Health Oganization [homepage on the Internet]. Geneva: The top 10 causes of death; 2018 Available from: http://www.who.int/news-room/fact-sheets/detail/the-top-10-causes-of-death. Accessed 041 2019
   Google Scholar
• Araujo-Gutierrez R, Ibarra-Cortez SH, Estep JD, et al. Incidence and outcomes of cancer treatment-related cardiomyopathy among referrals for advanced heart failure. Cardio-Oncology. 2018;4:3. doi:10.1186/s40959-018-0029-y
   PubMedGoogle Scholar
• Chang HM, Moudgil R, Scarabelli T, Okwuosa TM, Yeh ETH. Cardiovascular complications of cancer therapy: best practices in diagnosis, prevention, and management: part 1. J Am Coll Cardiol. 2017;70:2536–2551. doi:10.1016/j.jacc.2017.09.109629145954
   PubMed Web of Science ®Google Scholar
• Oliveira GH, Qattan MY, Al-Kindi S, Park SJ. Advanced heart failure therapies for patients with chemotherapy-induced cardiomyopathy. Circ Heart Fail. 2014;7(6):1050–1058. doi:10.1161/CIRCHEARTFAILURE.114.00129225415958
   PubMed Web of Science ®Google Scholar
• Menna P, Salvatorelli E. Primary prevention strategies for anthracycline cardiotoxicity: a brief overview. Chemotherapy. 2017;62:159–168. doi:10.1159/00045582328122377
   PubMed Web of Science ®Google Scholar
• European Medicines Agency [homepage on the Internet]. Amsterdam: Assessment report. Referral under Article 13 of Regulation (EC) No 1234/2008. Cardioxane; 2017 Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Referrals_document/Cardioxane_13/WC500232245.pdf Accessed 04 January 2019
   Google Scholar
• Korzeniowska K, Jankowski J, Cieślewicz A, Jabłecka A. Current approach for detection of sub-clinical left ventricular dysfunction associated with chemotherapy. Pharmacol Rep. 2015;67:1098–1102. doi:10.1016/j.pharep.2015.03.01026481527
   PubMed Web of Science ®Google Scholar
• Curigliano G, Cardinale D, Suter T, et al.; on behalf of the ESMO Guidelines Working Group. Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy. ESMO Clin Pract Guidelines Ann Oncol. 2012;7:155–166.
   Google Scholar
• Zamorano JL, Lancellotti P, Rodriguez Muñoz, et al. 2016 ESC position paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). Eur Heart J. 2016;37:2768–2801. doi:10.1093/eurheartj/ehw21127567406
   PubMed Web of Science ®Google Scholar
• Piepoli MF, Hoes AW, Agewall S, et al. European guidelines on cardiovascular disease prevention in clinical practice: the Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts) developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J. 2016;2016(37):2315–2381.
   Web of Science ®Google Scholar
• Salvatorelli E, Menna P, Cantalupo E, et al. The concomitant management of cancer therapy and cardiac therapy. Biochim Biophys Acta. 2015;1848:2727–2737. doi:10.1016/j.bbamem.2015.01.00325596534
   PubMed Web of Science ®Google Scholar
• Hullin R, Métrich M, Sarre A, et al. Diverging effects of enalapril or eplerenone in primary prevention against doxorubicin-induced cardiotoxicity. Cardiovasc Res. 2018;114:272–281. doi:10.1093/cvr/cvx16229016737
   PubMed Web of Science ®Google Scholar
• Nakamae H, Tsumura K, Terada Y, et al. Notable effects of angiotensin II receptor blocker, valsartan, on acute cardiotoxic changes after standard chemotherapy with cyclophosphamide, doxorubicin, vincristine, and prednisolone. Cancer. 2005;104:2492–2498. doi:10.1002/cncr.2147816247790
   PubMed Web of Science ®Google Scholar
• Imbaby S, Ewais M, Essawy S, Farag N. Cardioprotective effects of curcumin and nebivolol against doxorubicin-induced cardiac toxicity in rats. Hum Exp Toxicol. 2014;33(8):800–813. doi:10.1177/096032711452762824648241
   PubMed Web of Science ®Google Scholar
• Kaya MG, Ozkan M, Gunebakmaz O, et al. Protective effects of nebivolol against anthracycline-induced cardiomyopathy: a randomized control study. Int J Cardiol. 2013;167:2306–2310. doi:10.1016/j.ijcard.2012.06.02322727976
   PubMed Web of Science ®Google Scholar
• Kalay N, Basar E, Ozdogru I, et al. Protective effects of carvedilol against anthracycline-induced cardiomyopathy. J Am Coll Cardiol. 2006;48:2258–2262. doi:10.1016/j.jacc.2006.07.05217161256
   PubMed Web of Science ®Google Scholar
• Elitok A, Oz F, Cizgici AY, et al. Effect of carvedilol on silent anthracycline-induced cardiotoxicity assessed by strain imaging: a prospective randomized controlled study with six-month follow-up. Cardiol J. 2014;21:509–515. doi:10.5603/CJ.a2013.015024142687
   PubMed Web of Science ®Google Scholar
• Zamani B, Salehi R, Esfahani A. Protective effect of carvedilol against anthracycline-induced cardiomyopathy on patients with breast cancer and lymphoma. Int J Adv Med. 2018;5:16–20. doi:10.18203/2349-3933.ijam20180061
   Google Scholar
• Avila MS, Ayub-Ferreira SM, de Barros Wanderley MR Jr, et al. Carvedilol for prevention of chemotherapy-related cardiotoxicity: the CECCY trial. J Am Coll Cardiol. 2018;71:2281–2290. doi:10.1016/j.jacc.2018.02.04929540327
   PubMed Web of Science ®Google Scholar
• Kheiri B, Abdalla A, Osman M, et al. Meta-analysis of carvedilol for the prevention of anthracycline-induced cardiotoxicity. Am J Cardiol. 2018;122:1959–1964. doi:10.1016/j.amjcard.2018.08.03930292333
   PubMed Web of Science ®Google Scholar
• Pituskin E, Mackey JR, Koshman S, et al. Multidisciplinary approach to novel therapies in cardio-oncology research (MANTICORE 101-breast): a randomized trial for the prevention of trastuzumab-associated cardiotoxicity. J Clin Oncol. 2017;35:870–877. doi:10.1200/JCO.2016.68.783027893331
   PubMed Web of Science ®Google Scholar
• Georgakopoulos P, Roussou P, Matsakas E, et al. Cardioprotective effect of metoprolol and enalapril in doxorubicin-treated lymphoma patients: a prospective, parallel-group, randomized, controlled study with 36-month follow-up. Am J Hematol. 2010;85:894–896. doi:10.1002/ajh.2184020872550
   PubMed Web of Science ®Google Scholar
• Gulati G, Heck SL, Ree AH, et al. Prevention of cardiac dysfunction during adjuvant breast cancer therapy (PRADA): a 2×2 factorial, randomized, placebo-controlled, double-blind clinical trial of candesartan and metoprolol. Eur Heart J. 2016;37:1671–1680. doi:10.1093/eurheartj/ehw02226903532
   PubMed Web of Science ®Google Scholar
• Heck SL, Gulati G, Hoffmann P, et al. Effect of candesartan and metoprolol on myocardial tissue composition during anthracycline treatment: the PRADA trial. Eur Heart J Cardiovasc Imaging. 2018;19:544–552. doi:10.1093/ehjci/jex15929106497
   PubMed Web of Science ®Google Scholar
• Cardinale D, Colombo A, Sandri MT, et al. Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition. Circulation. 2006;114:2474–2481. doi:10.1161/CIRCULATIONAHA.106.63514417101852
   PubMed Web of Science ®Google Scholar
• Bosch X, Rovira M, Sitges M, et al. Enalapril and carvedilol for preventing chemotherapy-induced left entricular systolic dysfunction in patients with malignant hemopathies: the OVERCOME trial (preventiOn of left Ventricular dysfunction with enalapril and caRvedilol in patients submitted to intensive ChemOtherapy for the treatment of Malignant hEmopathies). J Am Coll Cardiol. 2013;61:2355–2362.23583763
   PubMed Web of Science ®Google Scholar
• Schwarz ER, Kersting PH, Reffelmann T, et al. Cardioprotection by carvedilol: antiapoptosis is independent of beta-adrenoceptor blockage in the rat heart. J Cardiovasc Pharmacol Ther. 2003;8:207–215. doi:10.1177/10742484030080030614506546
   PubMedGoogle Scholar
• Dessì M, Madeddu C, Piras A, et al. Long-term, up to 18 months, protective effects of the angiotensin II receptor blocker telmisartan on Epirubin-induced inflammation and oxidative stress assessed by serial strain rate. Springerplus. 2013;2:198. doi:10.1186/2193-1801-2-19823741643
   PubMed Web of Science ®Google Scholar
• Liu L, Liu ZZ, Liu YY, et al. Preventive effect of low-dose carvedilol combined with candesartan on the cardiotoxicity of anthracycline drugs in the adjuvant chemotherapy of breast cancer. Zhonghua Zhong Liu Za Zhi. 2013;35:936–940.24506965
   PubMedGoogle Scholar
• Boekhout AH, Gietema JA, Milojkovic Kerklaan B, et al. Angiotensin II–receptor inhibition with candesartan to prevent trastuzumab-related cardiotoxic effects in patients with early breast cancer. A randomized clinical Trial. JAMA Oncol. 2016;2:1030–1037. doi:10.1001/jamaoncol.2016.172627348762
   PubMed Web of Science ®Google Scholar
• Cadeddu C, Piras A, Mantovani G, et al. Protective effects of the angiotensin II receptor blocker telmisartan on epirubicin-induced inflammation, oxidative stress, and early ventricular impairment. Am Heart J. 2010;160:487.e1–487. doi:10.1016/j.ahj.2010.05.037
   PubMed Web of Science ®Google Scholar
• Akpek M, Ozdogru I, Sahin O, et al. Protective effects of spironolactone against anthracycline-induced cardiomyopathy. Eur J Heart Fail. 2015;17:81–89. doi:10.1002/ejhf.19625410653
   PubMed Web of Science ®Google Scholar
• Seicean S, Seicean A, Plana JC, Budd GT, Marwick TH. Effect of statin therapy on the risk for incident heart failure in patients with breast cancer receiving anthracycline chemotherapy: an observational clinical cohort study. J Am Coll Cardiol. 2012;60:2384–2390. doi:10.1016/j.jacc.2012.07.06723141499
   PubMed Web of Science ®Google Scholar
• Acar Z, Kale A, Turgut M, et al. Efficiency of ATORVASTATIN in the protection of anthracycline-induced cardiomyopathy. J Am Coll Cardiol. 2011;9:988–989. doi:10.1016/j.jacc.2011.05.025
   Web of Science ®Google Scholar
• Chotenimitkhun R, D’Agostino R Jr, Lawrence JA, et al. Chronic statin administration may attenuate early anthracycline-associated declines in left ventricular ejection function. Can J Cardiol. 2015;31:302–307. doi:10.1016/j.cjca.2014.11.02025662284
   PubMed Web of Science ®Google Scholar
• Calvillo-Argüelles O, Abdel-Qadir H, Michalowska M, et al. Cardioprotective effect of statins in patients with her2-positive breast cancer receiving trastuzumab therapy. Can J Cardiol. 2019;35:153–159. doi:10.1016/j.cjca.2018.11.02830760421
   PubMed Web of Science ®Google Scholar
• Cappetta D, Esposito G, Coppini R, et al. Effects of ranolazine in a model of doxorubicin-induced left ventricle diastolic dysfunction. Br J Pharmacol. 2017;174:3696–3712. doi:10.1111/bph.1379128320043
   PubMed Web of Science ®Google Scholar
• Corradi F, Paolini L, De Caterina R. Ranolazine in the prevention of anthracycline cardiotoxicity. Pharmacol Res. 2014;79:88–102. doi:10.1016/j.phrs.2013.11.00124269342
   PubMed Web of Science ®Google Scholar
• Mihos CG, Krishna RK, Kherada N, Larrauri-Reyes M, Tolentino A, Santana O. The use of ranolazine in non-angina cardiovascular disorders: a review of current data and ongoing randomized clinical trials. Pharmacol Res. 2016;103:49–55. doi:10.1016/j.phrs.2015.10.01826546970
   PubMed Web of Science ®Google Scholar
• Minotti G. Pharmacology at work for cardio-oncology: ranolazine to treat early cardiotoxicity induced by antitumor drugs. J Pharmacol Exp Ther. 2013;346:343–349. doi:10.1124/jpet.113.20405723818683
   PubMed Web of Science ®Google Scholar
• Tallarico D, Rizzo V, Di Maio F, et al. Myocardial cytoprotection by trimetazidine against anthracycline-induced cardiotoxicity in anticancer chemotherapy. Angiology. 2003;54:219–227. doi:10.1177/00033197030540021212678198
   PubMed Web of Science ®Google Scholar
• de Gregorio C, Potenza G, Ferraro G. Effectiveness of the combination therapy with lisinopril, ivabradine and multivitamin supplementation in anthracycline-induced severe cardiotoxicity. Int J Cardiol. 2014;176:1374–1376. doi:10.1016/j.ijcard.2014.07.27225131909
   PubMed Web of Science ®Google Scholar
• Colak MC, Parlakpinar H, Tasdemir S, et al. Therapeutic effects of ivabradine on hemodynamic parameters and cardiotoxicity induced by doxorubicin treatment in rat. Hum Exp Toxicol. 2012;31:945–954. doi:10.1177/096032711243828822354086
   PubMed Web of Science ®Google Scholar
• Okuma K, Furuta I, Ota K. Protective effect of coenzyme Q10 in cardiotoxicity induced by Adriamycin. Gan To Kagaku Ryoho. 1984;11:502–508.6703724
   PubMedGoogle Scholar
• Tsubaki K, Horiuchi A, Kitani T, et al. Investigation of the preventive effect of CoQ10 against the side-effects of anthracycline antineoplastic agents. Gan To Kagaku Ryoho. 1984;11:1420–1427.6742867
   PubMedGoogle Scholar
• Iarussi D, Auricchio U, Agretto A, et al. Protective effect of coenzyme Q10 on anthracyclines cardiotoxicity: control study in children with acute lymphoblastic leukemia and non-Hodgkin lymphoma. Mol Aspects Med. 1994;15:207–212. doi:10.1016/0098-2997(94)90030-2
   PubMed Web of Science ®Google Scholar
• Mustafa HN, Hegazy GA, Awdan SAE, AbdelBaset M. Protective role of CoQ10 or L-carnitine on the integrity of the myocardium in doxorubicin induced toxicity. Tissue Cell. 2017;49:410–426. doi:10.1016/j.tice.2017.03.00728410798
   PubMed Web of Science ®Google Scholar
• Chang VY, Wang JJ. Pharmacogenetics of chemotherapy-induced cardiotoxicity. Curr Oncol Rep. 2018;20:52. doi:10.1007/s11912-018-0696-829713898
   PubMed Web of Science ®Google Scholar
• Schneider BP, Shen F, Gardner L, et al. Genome-Wide Association Study for anthracycline-induced congestive heart failure. Clin Cancer Res. 2017;23:43–51. doi:10.1158/1078-0432.CCR-16-090827993963
   PubMed Web of Science ®Google Scholar